Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 13, 2005
Identification of hepatitis C virus 1b-derived peptides recognized by both cellular and humoral immune systems in HCV1b(+) HLA-A24(+) patientsMayumi Tamura, Akira Yamada, Yukari Takao, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 15, 2005
Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinomaYi Wang, Mamoru Harada, Hirohisa Yano, et al.
The Prostate|September 21, 2011
Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapyMasanori Noguchi, Fukuko Moriya, Shigetaka Suekane, et al.
International Journal of Molecular Medicine|November 8, 2006
Mitogen stimulation activates different signaling pathways in early- and late-divided T cells as revealed by cDNA microarray analysisYufeng Li, Kwong-Kwok Wong, Satoko Matsueda, et al.
Cancer Science|July 1, 2015
Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapyKouichiro Kawano, Naotake Tsuda, Kayoko Waki, et al.
Anticancer Research|April 1, 2009
Distinct patient responses to activation of T-cells by free HER-2, G89 (777-789) and protected LRMK-linked HER-2, {AE-39 [p776 (Ava-774-788)], AE-47 [(Ava-776-788)] and AE-37[p776 (774-788)]} peptides could lead to development of personalized cancer vaccinesYufeng Li, Satoko Matsueda, Clayton L Efferson, et al.
Oncology Reports|April 30, 2010
Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminates CD44 Hi progenitors of taxol-resistant ovarian cancer cellsTakashi Mine, Satoko Matsueda, Hui Gao, et al.
Cancer Science|June 17, 2017
Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapiesShigeru Yutani, Takahisa Shirahama, Daisuke Muroya, et al.
Journal of Medical Virology|May 29, 2009
A peptide derived from hepatitis C virus (HCV) core protein inducing cellular responses in patients with HCV with various HLA class IA allelesYamei Niu, Nobukazu Komatsu, Yoshihiro Komohara, et al.
Experimental and Therapeutic Medicine|September 13, 2012
Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosisMunehiro Yoshitomi, Shigeru Yutani, Satoko Matsueda, et al.
Pageof 9